|
|
Blood, 1 April 2006, Vol. 107, No. 7, pp. 2871-2878.
Prepublished online as a Blood First Edition Paper on December 8, 2005; DOI 10.1182/blood-2005-07-3014.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity
Pedro Horna,
Alex Cuenca,
Fengdong Cheng,
Jason Brayer,
Hong-Wei Wang,
Ivan Borrello,
Hyam Levitsky, and
Eduardo M. Sotomayor
From the Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL; and the Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD.
Bone marrow-derived antigen-presenting cells (APCs) play a central role in the induction of tolerance to tumor antigens expressed by B-cell lymphomas. Here we show that in vivo disruption of this APC-mediated tolerogenic mechanism unveils an intrinsic ability of malignant B cells to efficiently present tumor antigens to antigen-specific CD4+ T cells, resulting in a strong antitumor effect. This intrinsic antigen-presenting ability of malignant B cells is, however, overridden by tolerogenic bone marrow-derived APCs, leading instead to T-cell unresponsiveness and lack of antitumor effect. These results highlight the concept that therapeutic strategies aimed at enhancing the antigen-presenting function of B-cell lymphomas might not succeed unless the tolerogenic mechanisms mediated by bone marrow-derived APCs are disrupted in the first place.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Wang, F. Cheng, K. Wright, J. Tao, M. Smith, J. Pinilla, S. Dessureault, S. Sebti, and E.M. Sotomayor
Targeting STAT3 Signaling to Augment the Immunogenicity of B-Cell Lymphomas
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
708 - 708.
[Abstract]
|
|
|
|
|
|
|
M.-G. de Goer de Herve, A. Cariou, F. Simonetta, and Y. Taoufik
Heterospecific CD4 Help to Rescue CD8 T Cell Killers
J. Immunol.,
November 1, 2008;
181(9):
5974 - 5980.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Serafini, S. Mgebroff, K. Noonan, and I. Borrello
Myeloid-Derived Suppressor Cells Promote Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T Cells
Cancer Res.,
July 1, 2008;
68(13):
5439 - 5449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z.-Z. Yang, A. J. Novak, S. C. Ziesmer, T. E. Witzig, and S. M. Ansell
CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells
Blood,
October 1, 2007;
110(7):
2537 - 2544.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Chung, H. Qin, C.-Y. Kang, S. Kim, L. W. Kwak, and C. Dong
An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity
Blood,
September 15, 2007;
110(6):
2013 - 2019.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. R. French, V. Y. Taraban, G. R. Crowther, T. F. Rowley, J. C. Gray, P. W. Johnson, A. L. Tutt, A. Al-Shamkhani, and M. J. Glennie
Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation
Blood,
June 1, 2007;
109(11):
4810 - 4815.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z.-Z. Yang, A. J. Novak, S. C. Ziesmer, T. E. Witzig, and S. M. Ansell
Attenuation of CD8+ T-Cell Function by CD4+CD25+ Regulatory T Cells in B-Cell Non-Hodgkin's Lymphoma.
Cancer Res.,
October 15, 2006;
66(20):
10145 - 10152.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
